title: An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
abstract: A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclonal anti-CTLA-4 antibody) induced immune-mediated abscopal effects in poorly immunogenic pre-clinical tumor models and metastatic melanoma patients. However, no such reports exist for patients with metastatic lung adenocarcinoma. We report the first abscopal response in a treatment-refractory lung cancer patient treated with radiotherapy and ipilimumab. A post-treatment increase in tumor-infiltrating cytotoxic lymphocytes, tumor regression, and normalization of tumor markers was observed. One year after treatment with concurrent radiotherapy and ipilimumab the patient is without evidence of disease.
authors.affiliation: Department of Radiation Oncology, New York University School of Medicine, New York, NY.
authors.forename: Encouse B
authors.initials: EB
authors.lastname: Golden
authors.affiliation: Department of Radiation Oncology, New York University School of Medicine, New York, NY ; Department of Pathology, New York University School of Medicine, New York, NY.
authors.forename: Sandra
authors.initials: S
authors.lastname: Demaria
authors.affiliation: Department of Radiation Oncology, New York University School of Medicine, New York, NY.
authors.forename: Peter B
authors.initials: PB
authors.lastname: Schiff
authors.affiliation: Department of Medicine, New York University School of Medicine, New York, NY.
authors.forename: Abraham
authors.initials: A
authors.lastname: Chachoua
authors.affiliation: Department of Radiation Oncology, New York University School of Medicine, New York, NY.
authors.forename: Silvia C
authors.initials: SC
authors.lastname: Formenti
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy / Q000556:secondary*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy / Q000556:secondary*; D003131:Combined Modality Therapy; D006801:Humans; D000074324:Ipilimumab; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab